Edition:
United States

Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

47.55USD
4:00pm EDT
Change (% chg)

$0.65 (+1.39%)
Prev Close
$46.90
Open
$46.55
Day's High
$47.80
Day's Low
$46.40
Volume
132,734
Avg. Vol
270,804
52-wk High
$65.60
52-wk Low
$30.00

PCRX.OQ

Chart for PCRX.OQ

About

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid... (more)

Overall

Beta: 2.31
Market Cap(Mil.): $1,759.93
Shares Outstanding(Mil.): 37.53
Dividend: --
Yield (%): --

Financials

  PCRX.OQ Industry Sector
P/E (TTM): -- 29.17 29.94
EPS (TTM): -1.02 -- --
ROI: -12.98 13.48 13.01
ROE: -17.35 14.39 14.16

BRIEF-Trinity and Pacira announce collaboration to decrease opioid use nationwide

* Trinity Health and Pacira Pharmaceuticals announce collaboration to decrease opioid use nationwide

Mar 16 2017

BRIEF-Pacira says phase 4 study shows its drug reduces opioid consumption and postsurgical pain in patients undergoing total knee arthroplasty

* Phase 4 study shows exparel versus active comparator reduces opioid consumption and postsurgical pain in patients undergoing total knee arthroplasty

Mar 14 2017

BRIEF-Pacira Pharmaceuticals prices $300 mln aggregate principal amount of 2.375% convertible senior notes due 2022

* Pacira Pharmaceuticals announces pricing of $300 million aggregate principal amount of 2.375% convertible senior notes due 2022 Source text for Eikon: Further company coverage:

Mar 08 2017

BRIEF-Pacira Pharmaceuticals announces proposed offering of $300 million aggregate principal amount of convertible senior notes

* Announces proposed offering of $300 million aggregate principal amount of convertible senior notes

Mar 06 2017

BRIEF-Pacira Pharmaceuticals reports Q4 adj. earnings per share $0.09

* Pacira Pharmaceuticals reports 2016 financial results and provides business update

Mar 01 2017

BRIEF-Pacira Pharmaceuticals collaborates with Depuy Synthes to support promotion, education and training of exparel in orthopedics

* Pacira Pharmaceuticals announces collaboration with Depuy Synthes to support promotion, education and training of Exparel in orthopedics

Jan 25 2017

BRIEF-Pacira and Genealign announce partnership to develop low-opioid pain management protocols

* Pacira Pharmaceuticals and Genealign announce partnership to develop low-opioid pain management protocols for postsurgical patients at high risk of addiction Source text for Eikon: Further company coverage:

Nov 29 2016

BRIEF-Pacira Pharmaceuticals Q3 non-GAAP earnings per share $0.20

* Sees FY 2016 exparel net product sales of $263 million to $268 million

Nov 02 2016

More From Around the Web

Competitors

Earnings vs. Estimates